newsfilter
← Latest News
GlobeNewswire·

Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpointsSuccessfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and